Clinical Trial Update: A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of FS118 in patients with advanced and metastatic cancers, including head and neck squamous cell carcinoma, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• FS118

Snippet

Sponsor: invoX Pharma Limited | Conditions: Advanced Cancer, Metastatic Cancer | Phase 1, Phase 2 | Status: TERMINATED